TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Demichelis, Francesca; Fall, K.; Perner, S.; Andrén, O.; Schmidt, F.; Setlur, S. R.; Hoshida, Y.; Mosquera, J.; Pawitan, Y.; Lee, C.; Adami, H.; Mucci, L. A.; Kantoff, P. W.; Andersson, S.; Chinnaiyan, A. M.; Johansson, J.; Rubin, M. A.

doi:10.1038/sj.onc.1210237

CINECA IRIS Institutional Research Information System

IRIS è l'Anagrafe della ricerca dell'Università degli Studi di Trento, e ha lo scopo di raccogliere, documentare, diffondere e conservare le informazioni relative alla produzione scientifica degli autori afferenti all'Università degli Studi di Trento.

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50\% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15\% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95\% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

Scheda prodotto non validato

I dati visualizzati non sono stati ancora sottoposti a validazione formale da parte dello Staff di IRIS, ma sono stati ugualmente trasmessi al Sito Docente Cineca (Loginmiur).

Titolo:	TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
Autori Unitn:	Demichelis, Francesca K. Fall S. Perner O. Andrén F. Schmidt S. R. Setlur Y. Hoshida J. Mosquera Y. Pawitan C. Lee H. Adami L. A. Mucci P. W. Kantoff S. Andersson A. M. Chinnaiyan J. Johansson M. A. Rubin mostra contributor esterni nascondi contributor esterni
Anno di pubblicazione:	2007
Titolo del periodico:	ONCOGENE
Abstract:	The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50\% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15\% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95\% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.
Handle:	http://hdl.handle.net/11572/88989
Appare nelle tipologie:	03.1 Articolo su rivista (Journal article)

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11572/88989

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione